Shawn Patrick O'Brien and Kip Olmstead Bring Decades of Global Biotech Leadership and Marketing Experience to the King of Prussia-Based Company Disrupting Genetic Testing.
KING OF PRUSSIA, Pa. — Oct. 15, 2018 — Genomind®, an award-winning company advancing a unique personalized medicine platform, has strengthened it’s leadership with the appointment of two experienced global leaders, Shawn Patrick O’Brien as CEO, and Kip Olmstead as President, as well as the promotion of David Robbins to Chief Scientific Officer. The combined experience of O’Brien and Olmstead strengthens Genomind’s goal of bringing innovation to healthcare around the world with their two groundbreaking genetic tests, Genecept Assay®, and Mindful DNA Professional®
Shawn Patrick O’Brien, CEO
O’Brien is a global biotech and pharmaceutical executive leader with experience building highly successful enterprises. He has an extensive background in business development, marketing, selling, and licensing, as well as researching and developing innovations.
“Genomind has a stellar reputation for delivering actionable insights to clinicians, healthcare partners, and individuals to improve the quality of mental health. It’s an honor to build on that legacy.”, says O’Brien. “This is an exciting time in the field of pharmacogenetics, and I know everyone on the Genomind team is looking forward to growing the impact of our important work.”
Prior to Genomind, O’Brien founded and served as chair of Key BioPharma Partners, LLC, a private biopharma consulting firm. He also served as president and CEO of Cipher Pharmaceuticals Inc., AltheRx Pharmaceuticals Inc., Profectus BioSciences Inc. and Solstice NeuroSciences Inc., in addition to his multiple senior leadership roles within AstraZeneca.
In addition, O’Brien is board chair for Alto Pharma, a privately held company, and serves on the advisory boards of Greater Philadelphia Life Sciences Congress, and the Hubert J.P. Schoemaker Classic. He received his undergraduate science degree from the University of Western Ontario in Canada.
“Shawn’s impressive background and broad global healthcare experience in the US, UK, and Canada are the perfect fit for taking Genomind to the next level.” says Ronald I. Dozoretz, M.D., founder and chairman of Genomind. “Our colleagues, clinicians, patients, and other stakeholders will benefit from Shawn’s strategic leadership as he advances the work of our pioneering scientists and thought leaders in brain health and genetics.”
O’Brien replaces Thomas Hess, Genomind’s Chief Financial Officer who had been serving as interim CEO in addition to his CFO duties. Hess will remain with Genomind as Chief Financial Officer.
Speaking on behalf of the board, O’Brien said, “Tom has been instrumental in helping Genomind reach new heights. I speak for all of the leadership team when I say that we are immensely grateful for all of his time and effort, and stewardship of the office. I look forward to working with Tom, as he is a widely recognized leader in the life sciences community.”
Kip Olmstead, President
“I am pleased to announce the appointment of Kip Olmstead as President of Genomind” says O’Brien. “ Kip brings a wealth of consumer marketing leadership experience and a very strong customer focus to Genomind that will help us deliver on our expanding client needs”.
Olmstead brings 20+ years of consumer & professional brand building, sales, and marketing leadership to the team, as well as strong retail relationships, entrepreneurial marketing, and ecommerce experience. He’s held significant CPG & Healthcare CMO roles, and has senior leadership experience from his time at First Quality Enterprises, Crayola, and Procter and Gamble, working on big brands like Prilosec OTC, Oral-B, Duracell, and Prevail. Olmstead is a graduate of the United States Military Academy at West Point, N.Y.
Olmstead’s accomplishments in consumer brand building combined with O’Brien’s proven biotech leadership give Genomind a powerful edge for future success.
David Robbins, PhD, Chief Scientific Officer
“We are fortunate to have someone of David’s caliber step up to lead our scientific research and product development, as well as leading our lab through its initial and continued, CAP and NY state accrediations” says O’Brien. “David’s experience in research and product development will be key to launching Genomind to the next level.”
Robbins has over two decades of experience in clinical molecular diagnostic testing in the fields of genetics, oncology and infectious diseases. He previously served as Senior Vice President of Molecular Pathology and was the Laboratory Director at Genomind. Prior to joining Genomind, he founded the nucleic acids testing division of UTC Labs.. He has also served at SmithKline Clinical Labs (now Quest Diagnostics) and Abbott Labs.
Dr. Robbins received his BA in Chemistry from the Johns Hopkins University, and his PhD in Chemistry from the University of Texas at Austin. He holds a Diplomate from the American Board of Clinical Chemistry (DABCC) and an MT from the American Association of Bioanalysts.
Genomind® is a unique personalized medicine platform that brings innovation to healthcare around the world. Genomind, comprised of pioneering scientists and thought leaders in brain health, and genetics, delivers actionable insights to clinicians, healthcare partners, and individuals in order to improve the quality of human life. Learn more at www.genomind.com.
Genomind has been recognized for growth and excellence by Modern Healthcare, Life Sciences Pennsylvania, Inc. 5000, Philadelphia Business Journal and many others. It offers two genetic tests. Genecept Assay is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect, or cause adverse side-effects. Mindful DNA Professional provides evidence-based, personalized, actionable information that helps patients adjust their lifestyle, diet, habits and activities to improve their overall quality of life.
About the Genecept Assay
The Genecept Assay® is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, post-traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacogenomic consultation. Learn more.
About Mindful DNA®
Mindful DNA® is a genetic test used by clinicians that helps guide lifestyle, diet and/or nutritional supplement decisions to improve the overall health and wellbeing of patients. It was created based on Genomind’s expertise in brain health and belief in the importance of the mind-body connection. The results report provides personalized, actionable information that helps patients adjust their lifestyle, habits and activities to improve their quality of life. The test analyzes 32 genes in six key areas, or domains, of health: Cognition & Mental Acuity, Cardiometabolic, GI & Immune, Stress & Emotional Wellbeing, Inflammation and Sleep. For each at-risk gene result, the test report specifies holistic steps patients can take in collaboration with their healthcare provider to achieve better health. Learn more at www.genomind.com.
GENOMIND MEDIA CONTACTS:
Product Marketing Director, Genomind